New Once-Weekly shot shows promise for Long-Term hypoparathyroidism control
Disease control
Ongoing
This study looks at the long-term safety of an experimental drug called MBX 2109 for people with hypoparathyroidism, a condition where the body doesn't produce enough parathyroid hormone. About 60 adults who finished a 12-week phase 2 study will receive weekly injections of MBX 2…
Phase: PHASE2 • Sponsor: MBX Biosciences • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC